BRISTOL MYERS SQUIBB CO

The text above is an excerpt from the annual report of Bristol-Myers Squibb Company (BMS), a biopharmaceutical company. The company was incorporated in Delaware in 1933 and operates in the pharmaceutical industry, focusing on discovering, developing, licensing, manufacturing, marketing, and selling biopharmaceutical products globally. Its business strategy is to combine the resources and capabilities of a pharmaceutical company with the speed and focus of the biotech industry, with a focus on oncology, hematology, immunology, cardiovascular, and neuroscience. The company's significant products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyktu, Onureg, Inrebic, Augtyro, and Revlimid, among others. The company's website is [www.bms.com], and its ticker symbol is BMY. The company's business is divided into one segment and competes with other worldwide research-based drug companies, smaller research companies, and generic drug manufacturers. The company's products are sold worldwide, primarily to wholesalers, distributors, specialty pharmacies, and hospitals, and are subject to patent and regulatory exclusivity. The company has significant manufacturing operations in the US, Puerto Rico, Switzerland, Ireland, and the Netherlands. The company's revenue is primarily generated in the US and is divided into in-line products and new product portfolio. The company has undergone several acquisitions, divestitures, and licensing arrangements, including the acquisition of Mirati, the planned acquisitions of Karuna and RayzeBio, and a global strategic collaboration agreement with SystImmune. The company also has significant intellectual property, including patents and trademarks, and faces competition from generic and biosimilar drugs. The company's estimated minimum market exclusivity dates for its products vary, with some products facing patent expirations and regulatory exclusivity in the US, EU, and Japan.